Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BNT317 in Advanced Solid Tumors
NCT06750185Phase 2Recruiting
- Sponsor
- BioNTech SE
- Start
- Jan 2025
- Primary completion
- Apr 2031
- Countries
- 2
01
Overview
A Phase 2 trial of BNT317 in solid tumor (advanced stage), clear cell renal cell carcinoma (ccRCC), gastric cancer (GC), gastroesophageal junction cancer, non-small cell lung cancer (NSCLC), sponsored by BioNTech SE. Started Jan 2025; status: recruiting.
02
Drugs
BNT317
03
Conditions
solid tumor (advanced stage)clear cell renal cell carcinoma (ccRCC)gastric cancer (GC)gastroesophageal junction cancernon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06750185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06750185.